SCHEMBL13633849

SCHEMBL13633849

Cc1nc(-c2ccc(S(=O)(=O)Nc3cccc4cccnc34)s2)cs1

nearest known ligand 0.61

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
SLC40A1 Q9NP59 10/20 0.61
NFKBIA P25963 4/20 0.61
TDP1 Q9NUW8 4/20 0.61
RELA Q04206 3/20 0.61
KMT2A Q03164 3/20 0.61
MEN1 O00255 2/20 0.61
GLO1 Q04760 3/20 0.58
KDM4E B2RXH2 2/20 0.57
PKM P14618 1/20 0.57
PRNP P04156 1/20 0.56
RXFP1 Q9HBX9 1/20 0.56
POLB P06746 1/20 0.53
PFKFB3 Q16875 2/20 0.53
PFKFB4 Q16877 1/20 0.53
AGTR1 P30556 2/20 0.53
HTT P42858 2/20 0.53
MITF O75030 1/20 0.53
S1PR4 O95977 1/20 0.53
ALDH1A1 P00352 1/20 0.53
LMNA P02545 1/20 0.53

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL13633913 0.83 SLC40A1 (0.68) SLC40A1NFKBIATDP1RELAKMT2A
SCHEMBL13633882 0.79 SLC40A1 (0.63) SLC40A1NFKBIATDP1RELAKMT2A
SCHEMBL3817307 0.79 GABRA1 (0.61) SLC40A1NFKBIATDP1RELAKMT2A
SCHEMBL1424609 0.77 KDM4E (0.51) KDM4EPKMPRNPRXFP1POLB
SCHEMBL13633877 0.77 NFKBIA (1.00) SLC40A1NFKBIATDP1RELAKMT2A
SCHEMBL11995751 0.77 SLC40A1 (1.00) SLC40A1NFKBIATDP1RELAKMT2A
SCHEMBL13633914 0.76 SLC40A1 (0.61) SLC40A1NFKBIATDP1RELAKMT2A
SCHEMBL12230000 0.75 PRNP (0.66) KDM4EPKMPRNPRXFP1POLB
SCHEMBL13633881 0.75 PTGES2 (0.66) SLC40A1NFKBIATDP1RELAKMT2A
SCHEMBL13633885 0.74 SLC40A1 (0.56) SLC40A1NFKBIATDP1RELAKMT2A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8470821-B2 PDE4B inhibitors and uses therefor PLEXXIKON INC. (US) 2013-06-25 US disclosed
US-8470821-B2 PDE4B inhibitors and uses therefor PLEXXIKON INC. (US) 2013-06-25 US disclosed
US-20090286793-A1 PDE4B INHIBITORS AND USES THEREFOR PLEXXIKON, INC. 2009-11-19 US disclosed
US-20090286793-A1 PDE4B INHIBITORS AND USES THEREFOR PLEXXIKON, INC. 2009-11-19 US disclosed
US-7585859-B2 PDE4B inhibitors and uses therefor PLEXXIKON, INC. (US) 2009-09-08 US disclosed
US-7585859-B2 PDE4B inhibitors and uses therefor PLEXXIKON, INC. (US) 2009-09-08 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20090286793-A1 PDE4B INHIBITORS AND USES THEREFOR PDE4B, PDE7B, PDE4A SLC40A1 4638/4885NFKBIA 980/4885TDP1 83/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.